Foundation Medicine has struck a deal with an overseas firm to offer some of its assays in China. Under the terms of the deal reached with Shanghai-based WuXi PharmaTech Inc., the Cambridge, Mass.-based Foundation has licensed its FoundationOne assay to be performed in China. The FoundationOne assay forms complete genomic profiling of solid tumor cancers….
Foundation Medicine Strikes Deal for Testing in China
Foundation Medicine has struck a deal with an overseas firm to offer some of its assays in China. Under the terms of the deal reached with Shanghai-based WuXi PharmaTech Inc., the Cambridge, Mass.-based Foundation has licensed its FoundationOne assay to be performed in China. The FoundationOne assay forms complete genomic profiling of solid tumor cancers. […]